Industry
Biotechnology
HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
May 10, 2024 | 12:34 pm
Portfolio Pulse from Benzinga Newsdesk
May 09, 2024 | 9:10 pm
Portfolio Pulse from Benzinga Newsdesk
March 21, 2024 | 10:27 am
Portfolio Pulse from Benzinga Insights
March 20, 2024 | 9:30 pm
Portfolio Pulse from Benzinga Newsdesk
March 20, 2024 | 8:16 pm
Portfolio Pulse from Benzinga Newsdesk
January 08, 2024 | 12:13 pm
Portfolio Pulse from Benzinga Newsdesk
December 13, 2023 | 11:25 am
Portfolio Pulse from Benzinga Newsdesk
November 15, 2023 | 7:02 pm
Portfolio Pulse from Benzinga Newsdesk
November 10, 2023 | 8:26 pm
Portfolio Pulse from Benzinga Newsdesk
November 09, 2023 | 10:13 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.